By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Medivir AB 

Lunastigen 7

Huddinge    141 44  Sweden
Phone: 46-8-608-3100 Fax: 46-8-608-3199




GlaxoSmithKline (North Carolina) 

Peptimmune, Inc.  Development agreement for inhibitors of Cathepsin S for autoimmune and allergic diseases.

Company News
Medivir (MVRBF) Announces That Janssen Has Initiated An Open-Label Phase IIb Study Of The 3DAA Combination Of Simeprevir, Odalasvir And AL-335 (JNJ-4178) 11/28/2016 12:49:52 PM
Medivir (MVRBF) Beefs Up Cancer Pipeline With $238 Million Deal 11/3/2016 11:01:49 AM
TetraLogic (TLOG) Announces Agreements To Sell SMAC Mimetic And HDAC Inhibitor Assets To Medivir (MVRBF) And To Restructure Its Convertible Senior Notes And Delisting Of Common Stock 11/3/2016 10:59:19 AM
Medivir (MVRBF)’s Nucleotide Polymerase Inhibitor For The Treatment Of Liver Cancer, MIV-818, Enters Non-Clinical Development 11/1/2016 11:46:32 AM
Struggling Medivir (MVRBF) Divests Its Pharma Firm BioPhausia AB in $100 Million+ Deal 11/1/2016 5:47:27 AM
Medivir (MVRBF): MIV-711 Osteoarthritis Program: Enrollment In The Phase IIa Study Is Complete And Independent Safety Review Committee Again Recommends Go Ahead 10/27/2016 11:06:43 AM
Medivir (MVRBF) Slashes Jobs in Reorg, Company to Exclusively Focus on Oncology 10/10/2016 5:53:40 AM
Medivir (MVRBF): Updated Interim Phase IIa Data Demonstrate That The Combination Of Simeprevir, Odalasvir And AL-335 Has A High Level Of Efficacy In HCV Patients 9/26/2016 10:48:40 AM
Medivir (MVRBF): MIV-711 Osteoarthritis Trial: Recommendation To Go Ahead Based On Independent Review Of Safety Data, And First Patient Enrolled In Extension Study 9/23/2016 9:55:32 AM
Medivir (MVRBF): Interim Results From Phase IIa Trial Evaluating Triple Combination Including Simeprevir Demonstrates High Level Of Efficacy In HCV Patients 9/9/2016 10:53:25 AM